perpetuity. It is made available under a CC-BY 4.0 International license .

#### 1 Outcome of COVID-19 in hospitalised immunocompromised patients: an 2 analysis of the WHO ISARIC CCP-UK prospective cohort study.

- 3
- 4 Lance Turtle<sup>1,2\*</sup>, Mathew Thorpe<sup>3\*</sup>, Thomas M Drake<sup>3</sup>, Maaike Swets<sup>4</sup>, Carlo
- Palmieri<sup>5</sup>, Clark D Russell<sup>6</sup>, Antonia Ho<sup>7</sup>, Stephen Aston<sup>2,8</sup>, Daniel G Wootton<sup>1,2</sup>, 5
- Alex Richter<sup>9,10</sup>, Thushan I de Silva<sup>11</sup>, Hayley E Hardwick<sup>1</sup>, Gary Leeming<sup>12</sup>, Andy 6
- Law<sup>13</sup>, Peter JM Openshaw<sup>14</sup>, Ewen M Harrison<sup>3</sup>, ISARIC4C investigators, J 7
- Kenneth Baillie<sup>13,15<sup>\*\*</sup></sup>, Malcolm G Semple<sup>1,16<sup>\*\*</sup></sup>, Annemarie B Docherty<sup>3,15<sup>\*\*</sup></sup> 8
- 9

\* Equal contribution 10

- 11 \*\* Joint senior author
- 12

### 13 Affiliations

- 1 NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, 14
- Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, 15
- Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK 16
- 17 2 Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
- 3 Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK 18
- 19 4 Department of Infectious Diseases, Leiden University Medical Centre, Leiden
- University, Leiden, the Netherlands 20
- 21 5 Department of Molecular and Clinical Cancer Medicine, Institute of Systems,
- Molecular and Integrative Biology, University of Liverpool, Liverpool, UK 22
- 23 6 University of Edinburgh Centre for Inflammation Research, Queen's Medical 24 Research Institute, Edinburgh, UK
- 25 7 MRC-University of Glasgow Centre for Virus Research, University of Glasgow, 464 Bearsden Road, Glasgow, UK 26
- 27 8 Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- 9 Institute of Cancer and Genomic Science, College of Medical and Dental Science, 28 29 University of Birmingham, UK
- 30 10 University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- 11 Department of Infection, Immunity and Cardiovascular Disease, Medical School, 31 The University of Sheffield, Sheffield, UK 32
- 12 Department of Biostatistics, University of Liverpool, Liverpool, UK. 33
- 13 The Roslin Institute, Easter Bush campus, University of Edinburgh, Edinburgh, 34 35 UK
- 14 National Heart and Lung Institute, Imperial College London, London, UK 36
- 37 15 Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, UK
- 38 16 Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK
- 39 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 40 § Corresponding author:

- 41 Lance Turtle, Ronald Ross Building, Department of Clinical Infection, Microbiology
- 42 and Immunology, University of Liverpool, 8 West Derby Street, L69 7BE, Liverpool, UK.
- 43
- 44 lance.turtle@liverpool.ac.uk
- 45
- Running title: Immunocompromise and COVID-19 46
- 47 Keywords: Immunocompromise; Immunosuppression; SARS-CoV-2; COVID-19
- 48
- 49 Abstract word count: 254 including titles (249 without)
- Main text word count: 3,486 (30 references) 50
- 51

## 52 Abstract

### 53 Background

- 54 Immunocompromised patients may be at higher risk of mortality if hospitalised with
- 55 COVID-19 compared with immunocompetent patients. However, previous studies
- 56 have been contradictory. We aimed to determine whether immunocompromised
- 57 patients were at greater risk of in-hospital death, and how this risk changed over the
- 58 pandemic.

### 59 <u>Methods</u>

- 60 We included patients >=19yrs with symptomatic community-acquired COVID-19
- 61 recruited to the ISARIC WHO Clinical Characterisation Protocol UK. We defined
- 62 immunocompromise as: immunosuppressant medication preadmission, cancer
- 63 treatment, organ transplant, HIV, or congenital immunodeficiency. We used logistic
- regression to compare the risk of death in both groups, adjusting for age, sex,
- 65 deprivation, ethnicity, vaccination and co-morbidities. We used Bayesian logistic
- 66 regression to explore mortality over time.

### 67 <u>Findings</u>

- 68 Between 17/01/2020 and 28/02/2022 we recruited 156,552 eligible patients, of whom
- 69 21,954 (14%) were immunocompromised. 29% (n=6,499) of immunocompromised
- and 21% (n=28,608) of immunocompetent patients died in hospital. The odds of in-
- hospital mortality were elevated for immunocompromised patients (adjOR 1.44, 95%
- CI 1.39-1.50, p<0.001). As the pandemic progressed, in-hospital mortality reduced
- more slowly for immunocompromised patients than for immunocompetent patients.
- 74 This was particularly evident with increasing age: the probability of the reduction in
- hospital mortality being less for immunocompromised patients aged 50-69yrs was
   88% for men and 83% for women, and for those >80yrs was 99% for men, and 98%
- 88% for men and 83% for women, and for those >80yrs was 99% for men, and 98%
  for women.
- 78 Conclusions
- 79 Immunocompromised patients remain at elevated risk of death from COVID-19.
- 80 Targeted measures such as additional vaccine doses and monoclonal antibodies
- 81 should be considered for this group.
- 82 <u>Funding</u>
- 83 National Institute for Health Research; Medical Research Council; Chief Scientist
- 84 Office, Scotland.
- 85
- 86
- 87
- 88
- 89

#### Introduction 90

- 91 Coronavirus disease 2019 (COVID-19), the disease caused by severe acute
- 92 respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects older
- 93 people and those with underlying health conditions (1). However, a key challenge
- 94 throughout the pandemic has been to delineate which comorbidities confer the
- 95 greatest risk. Severe COVID-19 is an inflammatory process (2, 3), with several lines
- 96 of evidence suggesting that immune dysfunction is linked to adverse outcome (4, 5).
- 97 Consistent with this are clinical trial findings that anti-inflammatory treatments with
- 98 dexamethasone, tocilizumab and baricitinib improve survival in patients with
- 99 respiratory failure (6-8).
- Early data in the pandemic suggested a high mortality among immunocompromised 100
- 101 patients, with organ transplant recipients being at particular risk (9, 10). Studies have
- 102 compared mortality among immunocompromised patients with other patient groups
- 103 with COVID-19 with conflicting results. Some studies show increased mortality (11,
- 104 12), whereas others show no difference from other patient groups (13, 14). A
- 105 challenge when attributing risk to individual comorbidities has been that many factors
- are correlated. For example, some kidney transplant recipients also have abnormal 106
- 107 renal function which is itself a risk factor for poor outcome from COVID-19 (1, 15). A
- 108 large UK population study using routine health data from 17 million primary care
- 109 health records (OPENSafely) found that immunocompromising conditions, including 110 organ transplant and haematological malignancy, increased the risk of COVID-19
- 111 associated death (16). However, detailed information on disease severity at
- 112 presentation and events during hospitalisation were not available.
- As public health measures to control the spread of SARS-CoV-2 have now eased, 113
- 114 concern remains for the safety of those who are immunocompromised and whose
- 115 vaccination response may be compromised (17). Our aim was therefore to analyse
- one of the largest prospective cohorts of hospitalised COVID-19 cases, the ISARIC 116
- 117 WHO CCP-UK study dataset, to determine whether outcomes are worse in
- 118 immunocompromised patients, and whether the improved survival observed in
- 119 general over the course of the pandemic differed between immunocompromised and
- 120 immunocompetent patients.
- 121
- 122

### 123 Methods

### 124

#### 125 Study design and setting:

126 The ISARIC WHO Clinical Characterisation Protocol in the United Kingdom (CCP-UK) was activated on 17th January 2020 as part of the public health response to the 127 COVID-19 pandemic. CCP-UK prospectively recruited a cohort of >300,000 patients, 128 129 hospitalised with COVID-19, from 306 healthcare facilities across the UK. The 130 sample size was not pre-specified. The protocol, revision history, case report forms 131 and consent forms, are available online at isaric4c.net. The study received ethical 132 approval from the South Central - Oxford C Research Ethics Committee in England 133 (Ref: 13/SC/0149) and by the Scotland A Research Ethics Committee (Ref: 134 20/SS/0028). This study is reported according to the Strengthening the Reporting of 135 Observational Studies in Epidemiology (STROBE) guidelines for cohort studies. 136

### 137 Participants:

138 Adults (≥19yrs) who were admitted to hospital between 17th January 2020 and 28<sup>th</sup>

February 2022 with confirmed or highly suspected SARS-CoV-2 infection leading to 139

140 COVID-19 were included in this analysis: during the first wave, highly suspected

141 cases were also eligible for inclusion, because SARS-CoV-2 was an emergent

pathogen at that time and laboratory confirmation was dependent on availability of 142

143 testing. SARS-CoV-2 infection was confirmed using reverse-transcriptase

- 144 polymerase chain reaction (RT-PCR).
- 145 Data sources:

146 Data collected by research staff were entered into a standardised electronic case

147 report form within a secure Research Electronic Data Capture (REDCap) database.

148 Vaccination data were obtained from the national immunisation management system

149 (NIMS), and deterministically linked to the ISARIC CCP-UK REDCap data using

150 NHS number, which was collected as part of the ISARIC CCP-UK dataset.

151 Vaccination data were not available for Scottish patients and these analyses are

152 therefore restricted to only English and Welsh ISARIC CCP-UK participants with a

valid, linkable NHS number. Participants with invalid NHS numbers were excluded 153

154 from the analysis after December 2020 to allow accurate linkage with vaccination

155 data. Readmissions and those with erroneously recorded admission dates (eg, those

- 156 with admission dates outside the scope of the study) were also removed prior to
- analysis. 157
- 158
- 159 Variables:

160 Immunocompromise: We considered patients to be immunocompromised if they met

any of the following clinical criteria: solid organ transplant, active cancer diagnosis 161

and treatment, congenital immune deficiency, human immunodeficiency (HIV) 162

163 infection, in receipt of pre-admission immune-suppressive treatments, or pre-

admission oral or intravenous steroids (see online supplement). For the purposes of 164

165 analysis, these patients were only considered to be in one category, with the

166 underlying reason for being immunocompromised being categorised by the following

hierarchy: inherited immunological or metabolic disorder > solid organ transplant > 167

perpetuity. It is made available under a CC-BY 4.0 International license .

- 168 cancer > HIV > pre-admission immunosuppressants > pre-admission steroids.
- 169 Overlap between immunocompromising factors were visualised as part of the
- 170 analysis.
- 171

172 Participant characteristics: patient demographics including age, sex, comorbidities,

- 173 and ethnicity were recorded at hospital admission (see online supplement).
- 174 Deprivation index was calculated using hospital level geographical data provided by
- 175 the Office of National Statistics (ONS). Physiological parameters of the 4C Mortality
- 176 Score (18) were used as markers of illness severity at presentation: respiratory rate
- 177 (breaths per min), Glasgow Coma Scale, oxygen saturation (%), blood urea
- 178 (mmol/L), blood C-reactive protein (CRP, mg/L). Symptoms recorded on admission 179 are listed in the online supplement. If no symptom criteria were met, a patient was
- considered asymptomatic and was excluded from the analysis. If a patient met at 180
- 181 least one of the criteria, they were considered to be symptomatic and were included.
- 182
- In-hospital interventions were recorded including: critical care admission, level of 183
- respiratory support and treatments for COVID-19 including corticosteroids and 184
- 185 interleukin-6 receptor blockers. For steroid and anti-IL-6 treatments, analyses were
- 186 restricted to patients on oxygen therapy. Treatment with IL-6 receptor blockers was
- 187 indicated by national guidance for patients with a C-reactive protein (CRP) blood
- 188 level of 75mg/l or greater, or on respiratory support. Due to the nature of the data
- 189 collection, pre-admission steroids were assessed through a free text search of pre-
- 190 admission medication; dexamethasone, beclometasone, prednisolone,
- 191 cortisone/hydrocortisone or betamethasone were included.
- 192
- 193 Vaccination: to investigate the effect of vaccination, we considered patients having 194
- received no vaccine doses or within 20 days of the first vaccine dose as being 195 unprotected and therefore having no immunity to SARS-CoV-2; we then stratified
- patients as having received 1, 2, 3 and 4 or more doses, provided three weeks or 196
- 197 more had elapsed between the first vaccination and symptom onset or positive RT-
- 198 PCR test (whichever was earlier), or one week for subsequent doses, to allow
- 199 immunity to develop (19).
- 200
- Pandemic waves and SARS-CoV-2 variants: wave 1 was considered to be between 201 202 17<sup>th</sup> January 2020, the date that the study protocol was activated in the UK, and 31<sup>st</sup> 203 August 2020, the nadir of hospital inpatient numbers between the first and second 204 waves. This wave was largely accounted for by the B.1 lineage SARS-CoV-2 ancestral strain containing the D614G mutation. Wave 2 was defined as the period 205 from 1<sup>st</sup> September 2020 to 31<sup>st</sup> March 2021, and comprised a mixture largely of B.1 206 207 D614G lineages and the alpha variant (B.1.1.7). The third wave, during which the alpha variant was replaced by the delta variant (B.1.617.2), was between 1<sup>st</sup> April 208 209 2021 and 12<sup>th</sup> December 2021. From 13<sup>th</sup> December 2021 onwards, omicron 210 (B.1.1.529) became the dominant circulating variant in the UK and out-competed 211 delta (20). We refer to this period as the fourth wave.
- 212

- 213 Outcomes: the primary outcome was in-hospital mortality. Secondary outcomes were
- 214 the use of oxygen, non-invasive ventilation, invasive mechanical ventilation and
- 215 admission to critical care.
- 216
- 217 Missing data:

Due to the nature of such a large-scale, observational study, conducted during 218

- 219 pandemic surge conditions, high degrees of missingness exist in multiple variables,
- 220 particularly in the most recent wave dominated by the Omicron variant where
- 221 recruitment has waned over time. As this study is predominantly descriptive, we
- 222 have not performed any imputation to correct any data missingness, and instead are
- 223 providing descriptions of the data as it is known.
- 224
- 225 Statistical analyses:
- Continuous data are summarised as median (interguartile range) and categorical 226
- 227 data as frequency (percentage). We employed statistical disclosure control (SDC)
- 228 measures to protect patient confidentiality and anonymity.
- 229

230 To examine in-hospital mortality, we initially performed multivariable logistic

- 231 regression adjusted for age, sex, number of comorbidities, ethnicity, deprivation
- 232 index and vaccination (1). These variables were selected for inclusion in models
- 233 based on their important effects previously described by ourselves and others (1,
- 234 21). Other outcome measures were the use of oxygen, non-invasive ventilation,
- 235 intensive care admission and invasive ventilation, and were adjusted for the same
- 236 variables. We subsequently explored whether changes in in-hospital mortality over
- 237 time were different between immunocompetent and immunocompromised patients. A 238 Bayesian logistic regression model was specified with weakly informative priors on
- 239 model coefficients (four chains, 500 warmup, 2,000 iterations). The probability of
- 240 death was determined for immunocompromised and immunocompetent patients in
- 241 the first wave and the fourth wave, accounting for age, sex, socioeconomic
- 242 deprivation, and comorbidity count. We then calculated the absolute risk difference 243 for mortality in immunocompromised and immunocompetent patients in the first wave
- 244 and compared this with the absolute risk difference in the omicron wave. We set
- 245 comorbidity count to "2+", and deprivation score to "2", the most common level for
- 246 each variable, and stratified these results by sex, age category, and vaccination
- status. All analysis was performed using the statistical software package R version 247
- 248 4.1.1 including the use of the associated packages tidyverse, finalfit and brms.
- 249

#### 250 Results

### 251

Between 17th January 2020 and 28th February 2022, data for 304,628 admissions of 252 253 all ages were collected. Outcome data were available for 156,552 unique adult index 254 admissions with symptomatic COVID-19 and valid NHS numbers (Figure S1). 255 134,598 (86%) patients were classified as immunocompetent, and 21,954 (14%) 256 were immunocompromised (Figure S1). There was overlap between the immunocompromising conditions (Figure 1A), for example a large proportion of 257 258 patients with previous solid organ transplant were also taking immunosuppressive 259 medication. Using the hierarchical categorisation defined above, most patients that 260 were identified as immunocompromised were either those taking 261 immunosuppressive medication with no other documented immunocompromise (n=12,701 of 21,954, 58%), or those who had received recent cancer treatment 262 (n=5,116, 23%). The numbers of patients with other conditions were: congenital 263

- 264 immune deficiency (n=526, 2%), previous solid organ transplant (1,559, 7%),
- 265 HIV/AIDS (498, 2%) and pre-admission steroids (n=1,554, 7%).

266

267 The median age of the immunocompetent patients was 69.5 years (IQR 53.4 to 82.0), and was slightly younger than that of the immunocompromised group which 268 269 was 71.5 (IQR 58.7 to 80.3) (Table 1). Ages of immunocompromised patients varied 270 depending on the aetiology of their immunocompromise. Those with cancer (median 271 age 72.0. IQR (62.0 to 79.7)) and those on pre-admission immunosuppressants 272 (median 72.5, IQR (59.1 to 81.2)) or corticosteroids (75.1 (63.0 to 83.6)) were 273 considerably older than those with congenital immune deficiency (median 61.8, IQR 274 (45.3 to 77.2)), solid organ transplant (median 62.4 (IQR 52.1 to 72.0)) and HIV (57.8 275 (IQR 49.8 to 70.5)). 95% (n=20,801 of 21,954) of patients with immunocompromise 276 had at least one additional comorbidity (in addition to the reason for 277 immunocompromise). Chronic pulmonary disease (n=6,190 of 21,954, (28%), 278 immunocompromised) vs (n=18,495 of 134,598, (14%), immunocompetent), 279 haematologic disease (n=2,041 (9%)) vs (n=3,665 (2%)), rheumatologic disease 280 (n=4,540 (21%)) vs (n=12,901 (10%)), kidney disease (n=4,266 (19%)) vs (n=18,901 281 (14%)), and malignant neoplasm (n=5,113 (23%)) vs (n=8,484 (6%)) were more

- 282 common in immunocompromised vs immunocompetent patients. Diabetes (n=6,042
- 283 (28%) immunocompromised) vs (n=36,322 (27%) immunocompetent), obesity
- (n=2,945 (13%)) vs (n=17,462 (13%)), hypertension (n=9,758 (44%)) vs (n=57,117 284 285 (42%)), chronic cardiac disease (n=6,607 (30%)) vs (n=35,597 (26%)) were similar in 286 both groups (Table 1).

287

Overall, 85% (n=114,364 of 134,598) of immunocompetent and 81% (n=17,737 of 288 289 21,954) of immunocompromised patients hospitalised with COVID-19 were 290 unvaccinated - 49% (n=76,948 of 156,552) were admitted before vaccines were 291 available in waves 1 and 2 (Table 1, Figure S1). 5,112 (4%) of immunocompetent 292 and 789 (4%) of immunocompromised patients admitted had received one dose of 293 vaccine > 20 days earlier at the time of hospital admission. 11.601 (9%)294 immunocompetent and 2804 (13%) immunocompromised patients had received two 295 doses > 7 days earlier. 592 (<1%) immunocompetent and 290 (1%) of 296 immunocompromised patients had received 3 doses >7 days before the date of

- 297 hospital admission (Table 1). Over time, the relative proportion of
- 298 immunocompromised patients who were unvaccinated was less than for
- 299 immunocompetent patients (Figure S2).
- 300
- 301 Presenting symptoms and severity of illness:
- 302 Illness severity at presentation to hospital as measured by the physiological
- 303 components of the 4C Mortality Score was similar in the two groups at the beginning
- 304 of the pandemic, suggesting no difference in the threshold for admission for
- 305 immunocompromised patients (Figure 1B). Illness severity reduced in both groups
- 306 over the course of the pandemic, although to a lesser extent in the
- 307 immunocompromised group (Figure 1B and C). When compared with
- 308 immunocompetent patients, in the omicron wave immunocompromised patients had
- 309 higher respiratory rates (≥30bpm 67% vs immmunocompetent 57%), lower SaO<sub>2</sub>
- 310 (<92% 22% vs 15%), higher urea (urea ≥7mmol/l 49% vs 39%) and a higher inflammatory response (CRP ≥50mg/I 57% vs 47%) (Table S2, Figure 1C).
- 311
- 312
- 313 Treatments received:
- 314 When restricted to patients receiving oxygen, more patients in the
- 315 immunocompromised group received corticosteroids than the immunocompetent
- 316 group (Table S3, Figure S3). For patients on oxygen with a CRP>75, more
- 317 immunocompetent patients received tocilizumab compared with
- 318 immunocompromised patients (Table S3, Figure S4).
- 319
- 320 Outcomes:

321 Similar proportions of immunocompromised and immunocompetent patients received

- 322 oxygen therapy and were admitted to critical care. Immunocompromised patients
- 323 were more likely to receive non-invasive ventilation, and/or invasive mechanical
- 324 ventilation (Table 2). 6,499 (29%) immunocompromised patients died, compared
- with 28,608 (21%) immunocompetent patients. The highest mortality rates were seen 325 326 in patients with active cancer (n=1,818 (37%)) and those on pre-admission steroids
- 327 (n=517 (34%)) (Table S4).
- 328

329 After adjustment for age, sex, ethnicity, deprivation and comorbidities, the odds ratio 330 (OR) for death in the immunocompromised group was 1.44 (95% CI 1.39-1.5, p < 331 0.001) (Figure 2A). The ORs of several other outcomes were significantly different 332 for immunocompromised relative to immunocompetent patients, though with much 333 smaller effect sizes. The OR for receiving oxygen was 1.10 (95% CI 1.06, 1.15, 334 p<0.001), for critical care admission was 1.08 (95%CI 1.03, 1.13, p=0.001), receiving 335 non-invasive ventilation 1.17 (95%CI 1.12, 1.22, p<0.001), and invasive ventilation 336 1.10 (95%CI 1.03, 1.18, p=0.005) (Figure 2A).

- 337
- 338 Changes in mortality over time:
- 339 Mortality for both immunocompetent and immunocompromised groups reduced over 340 time. Crude in-hospital mortality of immunocompetent patients in the first wave was

- 30%, compared with 36% in immunocompromised patients. In the fourth (omicron) 341
- 342 wave, the mortality was 11% for immunocompetent patients, and 19% for
- 343 immunocompromised patients (Table 2).

344

345 After adjustment for age, sex, comorbidity count, deprivation and vaccination status, 346 compared with immunocompetent patients in wave 1, the OR for mortality remained 347 elevated in all waves in immunocompromised patients (Figure 2B). Univariable 348 analysis showed the same trend (Figure S5). In the fourth wave, nearly a year after 349 the vaccination program was initiated, the OR for death compared with the first wave 350 was 0.38 (95%CI 0.34, 0.42, p<0.001) for immunocompetent patients and 0.63 351 (95%CI 0.51, 0.76, p<0.001) for immunocompromised patients (Figure 2B). There 352 was a decline in the number of patients enrolled in the study over time (Figure S6).

353

354 To investigate this further, we calculated the difference in risk of death between the

- 355 first and fourth waves for both immunocompetent and immunocompromised patients.
- 356 using the Bayesian framework described in the methods, the probability that this
- 357 difference was less for immunocompromised patients (indicating less improvement
- 358 over the course of the pandemic) was always greater than 67% (Figure 3). Across all
- 359 ages, and both sexes, in-hospital mortality for immunocompromised patients 360 improved less than for immunocompetent patients. This was particularly evident with
- increasing age: the probability of the reduction in hospital mortality being less for 361
- 362 immunocompromised patients aged 50-69yrs was 88% for men and 83% for women,
- 363 and for those >80yrs was 99% for men, and 98% for women.

364

#### Discussion 365

### 366

Using the ISARIC CCP-UK cohort, we found that immunocompromised people 367 admitted to hospital with COVID-19 had greater adjusted mortality than the general 368 369 in-patient population. Mortality in this group has also not fallen to the same extent as 370 the immunocompetent patients. Over the course of the pandemic,

371 immunocompromised patients have seen less reduction in severity at presentation to

- 372 hospital and less improvement in in-hospital mortality than immunocompetent
- 373 patients.

374

375 Large population studies early in the pandemic have suggested that patients who are

376 immunocompromised are more likely to die from COVID-19 than those who are

377 immunocompetent (16). However, several studies, including one of the largest to

378 date (22), have not shown an increased risk of in-hospital mortality in

379 immunocompromised patients when compared to those with no known

380 immunodeficiency. One possible explanation for this is that immunocompromised

381 patients are more likely to be admitted to hospital, but once hospitalised, the

outcomes are similar. Our data challenge this hypothesis. Once admitted, the odds 382

383 of in-hospital mortality (adjusted for age, sex, ethnicity, vaccination and co-

384 morbidities) were higher for the immunocompromised group, with less improvement

385 in outcome over the course of the pandemic compared with the immunocompetent 386 group. Disease severity (physiological derangement) at presentation was similar for

the two groups early in the pandemic. Whilst severity at presentation has decreased 387

388 for both groups over time, as the pandemic progressed, the improvement seen was

- 389 greater for immunocompetent patients. Immunocompromised patients are now on
- 390 average more ill relative to immunocompetent patients. Other possibilities for

391 differences between studies potentially include selection of patient groups to include.

392 criteria for hospital admission and socio-ethnodemographic variation.

393

394 Immunocompromised patients with COVID-19 received steroids more frequently

395 during their admission than immunocompetent patients. This might indicate a

396 continuation of pre-admission, non-covid related steroid treatment. The less frequent

397 use of tocilizumab, on the other hand (in patients who met the criteria for use), may

398 indicate concern about the net state of immune suppression and careful weighing of

399 risk benefit in the minds of treating clinicians. To better inform the use of anti-

- 400 inflammatory treatments in this group, future studies targeted at
- 401 immunocompromised patients, or with recruitment stratified by immune status, would
- 402 be needed.

403

404 There was a reduction over time in the proportion of patients admitted after

vaccination compared with those unvaccinated. However, the risk difference 405

406 between immunocompromised and immunocompetent patients widened between the

407 first wave, and the fourth wave, by which time vaccination levels in the population

408 were high. In combination with our earlier work (23), this indicates that this group of

409 patients may remain more vulnerable than the general population even after

410 vaccination. Selection of SARS-CoV-2 variants is largely a function of transmissibility

411 (24, 25), or immune escape (26), and a future variant could still have higher intrinsic

412 virulence than omicron. In this case, immunocompromised patients might be more

- 413 vulnerable despite vaccination.
- 414

Our findings differ to those of Andersen et al. (22), which did not find an increase in 415 416 mortality in immunocompromised patients from 42 US health systems. A difference 417 in age may explain this discrepancy. The mean age of patients reported by Andersen 418 et al. (59 years) was younger than our median age (71.5 years), suggesting that the 419 difference between the two studies could be that here we are describing an older, 420 more co-morbid population. In our study chronic pulmonary, haematologic, 421 rheumatologic, kidney and liver disease were all more common in 422 immunocompromised patients, which may reflect either the reasons for 423 immunosuppression, or complications thereof. However, comorbidities such as heart 424 disease and hypertension were not more common in the immunocompromised 425 patients, indicating that differences in comorbidity were not the only reason for the 426 difference in outcomes between the groups.

427

428 The ISARIC CCP-UK cohort is one of the largest datasets of hospitalised patients 429 with COVID-19 in the world and has enabled us to study small subgroups such as 430 those with congenital immune deficiencies, which have not been captured in smaller 431 cohorts. The ISARIC CCP-UK dataset has detailed information regarding severity of 432 illness at presentation which allowed us to explore whether the threshold for hospital 433 admission differed between patient groups. We were also able to follow patient 434 journeys through the hospital looking at in-hospital interventions and respiratory 435 support which are lacking from routine healthcare datasets. There are some 436 weaknesses to this study. We did not collect data on the detailed drug histories of 437 patients prior to admission, and so we did not have information on which drug was 438 responsible for immunocompromise. We lacked data on pre-admission steroid 439 doses, meaning that we were unable to assess the extent to which steroid use 440 contributed to immune compromise. Missing data in the medical and drug histories 441 means that we may have underestimated the overall effect size by categorising

- some immunocompromised patients as immunocompetent.
- 443

444 We have observed that in hospital mortality for patients who are clinically extremely 445 vulnerable with immunocompromise has fallen less than for than immunocompetent patients in the ISARIC CCP-UK dataset. Despite the benefits of vaccination, this 446 447 group still lags behind the general patient population in the improvements in 448 outcomes after hospitalisation. A number of interventions, such as remdesivir, 449 molnupiravir and nirmatrelvir/ritonavir are now available to reduce the risk of progression to severe COVID-19 and hospitalisation in this patient group (27, 28). 450 451 However, some immunocompromised patients do not respond well to COVID-19 452 vaccines (29). and several monoclonal antibody treatments have now ceased to be 453 effective due to antigenic variation of the omicron variant (30). However, 454 tixagevimab/cilgavimab retains activity against omicron sub-variants BA.2. BA.4 and 455 BA.5, but is not available for routine clinical care in the UK. The use of tixagevimab/cilgavimab remains a policy option and may close the gap between 456 457 immunocompromised patients and the general population.

458

459

#### 460 **Acknowledgements**

461

This work is supported by grants from: the National Institute for Health Research 462 (NIHR) [award CO-CIN-01], the Medical Research Council [grant MC PC 19059] 463 464 and MR/V028979/1], the Chief Scientist Office, Scotland, and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University 465 466 of Liverpool in partnership with the UK Health Security Agency (UK-HSA), in 467 collaboration with Liverpool School of Tropical Medicine and the University of Oxford 468 [award 200907], NIHR HPRU in Respiratory Infections at Imperial College London 469 with UK-HSA [award 200927], Wellcome Trust and Department for International 470 Development [215091/Z/18/Z], the Bill and Melinda Gates Foundation 471 [OPP1209135], Liverpool Experimental Cancer Medicine Centre (Grant Reference: 472 C18616/A25153), NIHR Biomedical Research Centre at Imperial College London 473 [IS-BRC-1215-20013], EU Platform for European Preparedness Against (Re-) 474 emerging Epidemics (PREPARE) [FP7 project 602525]. We acknowledge the NIHR 475 Clinical Research Network for providing infrastructure support for this research. This 476 research is part of the Data and Connectivity National Core Study, led by Health 477 Data Research UK in partnership with the Office for National Statistics and funded by 478 UK Research and Innovation (grant ref MC PC 20029). LT is supported by a 479 Wellcome Trust clinical career development fellowship a [205228/Z/16/Z]. PJMO is 480 supported by a NIHR Senior Investigator Award [award 201385]. DGW is supported by an NIHR Advanced Fellowship [NIHR300669]. For the purpose of Open Access, 481 the authors have applied a CC-BY public copyright licence to any Author Accepted 482 483 Manuscript version arising from this submission. The views expressed are those of 484 the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome 485 Trust or UK-HSA.

486

#### 487 Data availability

488 This work uses data provided by patients and collected by the NHS as part of their 489 care and support #DataSavesLives. The CO-CIN data was collated by ISARIC4C 490 Investigators. ISARIC4C welcomes applications for data and material access

- 491 through our Independent Data and Material Access Committee (https://isaric4c.net).
- 492

### 493 **ISARIC4C** investigators:

494

495 \*Co-Lead Investigator (Consortium Lead): J Kenneth Baillie.

496 \*Co-Lead Investigator (Sponsor & Protocol CI): Malcolm G Semple.

497 \*Co-Lead Investigator (Imperial College): Peter JM Openshaw.

498

499 Co-Investigator: Beatrice Alex, Petros Andrikopoulos, Benjamin Bach, Wendy S

500 Barclay, Debby Bogaert, Meera Chand, Kanta Chechi, Graham S Cooke, Ana da

501 Silva Filipe, Thushan de Silva, Annemarie B Docherty, Gonçalo dos Santos Correia,

502 Marc-Emmanuel Dumas, Jake Dunning, Tom Fletcher, Christoper A Green, William

503 Greenhalf, Julian L Griffin, Rishi K Gupta, Ewen M Harrison, Julian A Hiscox,

Antonia Ying Wai Ho, Karl Holden, Peter W Horby, Samreen Ijaz, Saye Khoo, Paul 504 505 Klenerman, Andrew Law, Matthew R Lewis, Sonia Liggi, Wei Shen Lim, Lynn

- 506 Maslen, Alexander J Mentzer, Laura Merson, Alison M Meynert, Shona C Moore,
- 507 Mahdad Noursadeghi, Michael Olanipekun, Anthonia Osagie, Massimo Palmarini,
- 508 Carlo Palmieri, William A Paxton, Georgios Pollakis, Nicholas Price, Andrew

- Rambaut, David L Robertson, Clark D Russell, Vanessa Sancho-Shimizu, Caroline J 509
- 510 Sands, Janet T Scott, Louise Sigfrid, Tom Solomon, Shiranee Sriskandan, David
- Stuart, Charlotte Summers, Olivia V Swann, Zoltan Takats, Panteleimon Takis, 511
- 512 Richard S Tedder, AA Roger Thompson, Emma C Thomson, Ryan S Thwaites,
- 513 Lance CW Turtle, Maria Zambon.
- Data Analyst: Thomas M Drake, Cameron J Fairfield, Stephen R Knight, Kenneth A 514
- Mclean, Derek Murphy, Lisa Norman, Riinu Pius, Catherine A Shaw. 515
- Data and Information System Manager: Marie Connor, Jo Dalton, Carrol Gamble, 516
- Michelle Girvan, Sophie Halpin, Janet Harrison, Clare Jackson, James Lee, Laura 517
- Marsh, Daniel Plotkin, Stephanie Roberts, Egle Saviciute. 518
- 519 Data Integration and Presentation: Sara Clohisey, Ross Hendry, Susan Knight, Eva
- 520 Lahnsteiner, Andrew Law, Gary Leeming, Lucy Norris, James Scott-Brown, Sarah 521 Tait, Murray Wham.
- 522 ISARIC Clinical Coordinator: Gail Carson.
- 523 Edinburgh Laboratory Staff and Volunteers: Richard Clark, Audrey Coutts, Lorna
- 524 Donnelly, Angie Fawkes, Tammy Gilchrist, Katarzyna Hafezi, Louise MacGillivray,
- 525 Alan Maclean, Sarah McCafferty, Kirstie Morrice, Lee Murphy, Nicola Wrobel.
- 526 Local Principal Investigators: Kayode Adeniji, Daniel Agranoff, Ken Agwuh, Dhiraj
- Ail, Erin L. Aldera, Ana Alegria, Sam Allen, Brian Angus, Abdul Ashish, Dougal 527
- Atkinson, Shahedal Bari, Gavin Barlow, Stella Barnass, Nicholas Barrett, Christopher 528
- 529 Bassford, Sneha Basude, David Baxter, Michael Beadsworth, Jolanta Bernatoniene,
- 530 John Berridge, Colin Berry, Nicola Best, Pieter Bothma, Robin Brittain-Long, Naomi
- 531 Bulteel, Tom Burden, Andrew Burtenshaw, Vikki Caruth, David Chadwick, David
- Chadwick, Duncan Chambler, Nigel Chee, Jenny Child, Srikanth Chukkambotla, 532 Tom Clark, Paul Collini, Catherine Cosgrove, Jason Cupitt, Maria-Teresa Cutino-533
- 534 Moguel, Paul Dark, Chris Dawson, Samir Dervisevic, Phil Donnison, Sam
- Douthwaite, Andrew Drummond, Ingrid DuRand, Ahilanadan Dushianthan, Tristan 535
- 536 Dyer, Cariad Evans, Chi Eziefula, Chrisopher Fegan, Adam Finn, Duncan Fullerton,
- Sanjeev Garg, Sanjeev Garg, Atul Garg, Effrossyni Gkrania-Klotsas, Jo Godden, 537
- 538 Arthur Goldsmith, Clive Graham, Tassos Grammatikopoulos, Elaine Hardy, Stuart
- 539 Hartshorn, Daniel Harvey, Peter Havalda, Daniel B Hawcutt, Maria Hobrok, Luke
- 540 Hodgson, Anil Hormis, Joanne Howard, Michael Jacobs, Susan Jain, Paul Jennings,
- Agilan Kaliappan, Vidva Kasipandian, Stephen Kegg, Michael Kelsev, Jason 541 542 Kendall, Caroline Kerrison, Ian Kerslake, Oliver Koch, Gouri Koduri, George Koshy,
- 543 Shondipon Laha, Steven Laird, Susan Larkin, Tamas Leiner, Patrick Lillie, James
- 544 Limb, Vanessa Linnett, Jeff Little, Mark Lyttle, Michael MacMahon, Emily
- MacNaughton, Ravish Mankregod, Huw Masson, Elijah Matovu, Katherine 545
- McCullough, Ruth McEwen, Manjula Meda, Gary Mills, Jane Minton, Mariyam 546
- 547 Mirfenderesky, Kavya Mohandas, Quen Mok, James Moon, Elinoor Moore, Patrick
- Morgan, Craig Morris, Katherine Mortimore, Samuel Moses, Mbiye Mpenge, 548
- 549 Rohinton Mulla, Michael Murphy, Thapas Nagarajan, Megan Nagel, Mark Nelson,
- 550 Lillian Norris, Matthew K. O'Shea, Marlies Ostermann, Igor Otahal, Mark Pais, Carlo 551 Palmieri, Selva Panchatsharam, Danai Papakonstantinou, Padmasayee Papineni,
- 552 Hassan Paraiso, Brij Patel, Natalie Pattison, Justin Pepperell, Mark Peters, Mandeep
- Phull, Stefania Pintus, Tim Planche, Frank Post, David Price, Rachel Prout, Nikolas 553
- 554 Rae, Henrik Reschreiter, Tim Reynolds, Neil Richardson, Mark Roberts, Devender
- 555 Roberts, Alistair Rose, Guy Rousseau, Bobby Ruge, Brendan Ryan, Taranprit
- 556 Saluja, Sarah Cole, Matthias L Schmid, Aarti Shah, Manu Shankar-Hari, Prad
- 557 Shanmuga, Anil Sharma, Anna Shawcross, Jagtur Singh Pooni, Jeremy Sizer,
- Richard Smith, Catherine Snelson, Nick Spittle, Nikki Staines, Tom Stambach, 558

perpetuity. It is made available under a CC-BY 4.0 International license .

Richard Stewart, Pradeep Subudhi, Tamas Szakmany, Kate Tatham, Jo Thomas, 559 Chris Thompson, Robert Thompson, Ascanio Tridente, Darell Tupper-Carey, Mary 560 561 Twagira, Nick Vallotton, Rama Vancheeswaran, Lisa Vincent-Smith, Shico 562 Visuvanathan, Alan Vuylsteke, Sam Waddy, Rachel Wake, Andrew Walden, 563 Ingeborg Welters, Tony Whitehouse, Paul Whittaker, Ashley Whittington, Meme 564 Wijesinghe, Martin Williams, Lawrence Wilson, Stephen Winchester, Martin Wiselka, Adam Wolverson, Daniel G Wootton, Andrew Workman, Bryan Yates, Peter Young. 565 566 Material Management: Sarah E McDonald, Victoria Shaw. Outbreak Laboratory Staff and Volunteers: Katie A. Ahmed, Jane A Armstrong, 567 Milton Ashworth, Innocent G Asiimwe, Siddharth Bakshi, Samantha L Barlow, Laura 568 569 Booth, Benjamin Brennan, Katie Bullock, Nicola Carlucci, Emily Cass, Benjamin WA 570 Catterall, Jordan J Clark, Emily A Clarke, Sarah Cole, Louise Cooper, Helen Cox, 571 Christopher Davis, Oslem Dincarslan, Alejandra Doce Carracedo, Chris Dunn, Philip 572 Dyer, Angela Elliott, Anthony Evans, Lorna Finch, Lewis WS Fisher, Lisa Flaherty, 573 Terry Foster, Isabel Garcia-Dorival, Philip Gunning, Catherine Hartley, Anthony 574 Holmes, Rebecca L Jensen, Christopher B Jones, Trevor R Jones, Shadia 575 Khandaker, Katharine King, Robyn T. Kiy, Chrysa Koukorava, Annette Lake, 576 Suzannah Lant, Diane Latawiec, Lara Lavelle-Langham, Daniella Lefteri, Lauren 577 Lett, Lucia A Livoti, Maria Mancini, Hannah Massey, Nicole Maziere, Sarah 578 McDonald, Laurence McEvoy, John McLauchlan, Soeren Metelmann, Nahida S 579 Miah, Joanna Middleton, Joyce Mitchell, Shona C Moore, Ellen G Murphy, Rebekah 580 Penrice-Randal, Jack Pilgrim, Tessa Prince, Will Reynolds, P. Matthew Ridley, Debby Sales, Victoria E Shaw, Rebecca K Shears, Benjamin Small, Krishanthi S 581 582 Subramaniam, Agnieska Szemiel, Aislynn Taggart, Jolanta Tanianis-Hughes, Jordan 583 Thomas, Erwan Trochu, Libby van Tonder, Eve Wilcock, J. Eunice Zhang. 584 Patient Engagement: Seán Keating. Project Administrator: Cara Donegan, Rebecca G. Spencer, Lauren Obosi. 585 586 Project Manager: Chloe Donohue, Fiona Griffiths, Hayley Hardwick, Wilna 587 Oosthuvzen. 588 589 590

- 591
- 592
- 593

# perpetuity. It is made available under a CC-BY 4.0 International license .

### 594 References

595

596 Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. 1. 597 Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 598 599 2020 May 22;369:m1985.32444460 Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randal 600 2. 601 R, et al. Tissue-Specific Immunopathology in Fatal COVID-19. American Journal of Respiratory and Critical Care Medicine. 2021;203(2):192-201 602 Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, 603 3. 604 Moore SC, et al. Inflammatory profiles across the spectrum of disease reveal a 605 distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021 Mar 606 10;6(57).33692097 607 4. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, 608 Weisman AR, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Science Immunology. 2020;5(49):eabd7114 609 610 Hoepel W, Chen HJ, Geyer CE, Allahverdiyeva S, Manz XD, de Taeye SW, et 5. al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote 611 612 inflammation by alveolar macrophages. Sci Transl Med. 2021 Jun 613 2;13(596).33979301 614 Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. 6. 615 Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.32678530 616 Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. 617 7. 618 Interleukin-6 Receptor Antagonists in Critically III Patients with Covid-19. N Engl J 619 Med. 2021 Apr 22;384(16):1491-502.33631065 Horby PW, Emberson JR, Mafham M, Campbell M, Peto L, Pessoa-Amorim 620 8. 621 G, et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a 622 randomised, controlled, open-label, platform trial and updated meta-analysis. 2022. 623 9. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. 624 COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. 625 American Journal of Transplantation. 2020;20(7):1800-8 626 10. Azzi Y. Parides M. Alani O. Loarte-Campos P. Bartash R. Forest S. et al. 627 COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. 628 Kidney International. 2020;98(6):1559-67 629 Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, et al. Is 11. 630 COVID-19 infection more severe in kidney transplant recipients? American Journal 631 of Transplantation. 2021;21(3):1295-303 Fisher AM, Schlauch D, Mulloy M, Dao A, Reyad AI, Correll M, et al. 632 12. Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to 633 634 a matched cohort of non-transplant patients at a national healthcare system in the United States. Clinical Transplantation. 2021;35(4) 635 Andersen KM, Mehta HB, Palamuttam N, Ford D, Garibaldi BT, Auwaerter 636 13. 637 PG, et al. Association Between Chronic Use of Immunosuppresive Drugs and 638 Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A 639 Retrospective Cohort Study in a Large US Health System. Clinical Infectious 640 Diseases. 2021;73(11):e4124-e30 Gatti M, Rinaldi M, Bussini L, Bonazzetti C, Pascale R, Pasquini Z, et al. 641 14. 642 Clinical outcome in solid organ transplant recipients affected by COVID-19 compared

perpetuity. It is made available under a CC-BY 4.0 International license .

643 to general population: a systematic review and meta-analysis. Clin Microbiol Infect. 2022 Mar 12.35289294 644 645 Ozturk S, Turgutalp K, Arici M, Odabas AR, Altiparmak MR, Aydin Z, et al. 15. 646 Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis 647 and renal transplant patients compared with patients without kidney disease: a 648 nationwide analysis from Turkey. Nephrology Dialysis Transplantation. 649 2020;35(12):2083-95 650 16. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. 651 Factors associated with COVID-19-related death using OpenSAFELY. Nature. 652 2020;584(7821):430-6 653 17. Ryan L. Vaccinated but Not Protected—Living Immunocompromised During 654 the Pandemic. JAMA. 2021;325(24):2443 655 Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk 18. 656 stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality 657 658 Score. BMJ. 2020 Sep 9;370:m3339.32907855 659 19. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 660 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 661 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet. 2021;397(10286):1725-35 662 Paton RS, Overton CE, Ward T. The rapid replacement of the Delta variant by 663 20. Omicron (B.1.1.529) in England. Sci Transl Med. 2022 May 3:eabo5395.35503007 664 Docherty AB, Mulholland RH, Lone NI, Cheyne CP, De Angelis D, Diaz-Ordaz 665 21. 666 K, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre 667 prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Jul;9(7):773-85.34000238 668 669 22. Andersen KM, Bates BA, Rashidi ES, Olex AL, Mannon RB, Patel RC, et al. 670 Long-term use of immunosuppressive medicines and in-hospital COVID-19 671 outcomes: a retrospective cohort study using data from the National COVID Cohort 672 Collaborative. The Lancet Rheumatology. 2022;4(1):e33-e41 Egan C, Turtle L, Thorpe M, Harrison EM, Semple MG, Docherty AB. Hospital 673 23. 674 admission for symptomatic COVID-19 and impact of vaccination: analysis of linked 675 data from the Coronavirus Clinical Information Network and the National 676 Immunisation Management Service. Anaesthesia. 2022 Feb 18.35178709 677 Hart WS, Miller E, Andrews NJ, Waight P, Maini PK, Funk S, et al. Generation 24. 678 time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. The 679 Lancet Infectious Diseases. 2022 Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et 680 25. al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern 681 682 as at June 2021. Eurosurveillance. 2021;26(24) Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, 683 26. 684 et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews 685 Microbiology. 2021;19(7):409-24 Jayk Bernal A, Gomes Da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez 686 27. A. Delos Reves V. et al. Molnupiravir for Oral Treatment of Covid-19 in 687 Nonhospitalized Patients. New England Journal of Medicine. 2022;386(6):509-20 688 Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early 689 28. 690 Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England 691 Journal of Medicine. 2022;386(4):305-15

- 29. Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy 692
- of covid-19 vaccines in immunocompromised patients: systematic review and meta-693 694 analysis. BMJ. 2022:e068632
- Takashita E, Yamayoshi S, Simon V, Van Bakel H, Sordillo EM, Pekosz A, et 695 30.
- al. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and 696
- BA.5 Subvariants. New England Journal of Medicine. 2022; Epub ahead of print. 697
- 10.1056/nejmc2207519 698

699

### **Tables and figures**

# Table 1. Demographics and comorbidities for immunocompetent and immunocompromised patients in the ISARIC WHO CCP-UKstudy. The immunocompromised patients are presented as both the, incorporating all conditions leading to immunocompromise, and by eachgroup defined on the case record form.

label	Total N	Missing N	levels	Immunocompetent	Immunocompromised – Total	Immunocompromised - Pre-Existing Immunological Disorder	Immunocompromised - Previous Organ Transplant	Immunocompromised - Cancer	Immunocompromised - HIV	Immunocompromised - Pre-Admission Immunosuppressants	Immunocompromised - Pre-Admission Steroids
Total N (%)				134598 (86.0)	21954 (14.0)	526 (0.3)	1559 (1.0)	5116 (3.3)	498 (0.3)	12701 (8.1)	1554 (1.0)
Age on admission (years)	156538 (100.0)	14	Median (IQR)	69.5 (53.4 to 82.0)	71.5 (58.7 to 80.3)	61.8 (45.3 to 77.2)	62.4 (52.1 to 72.0)	72.0 (62.0 to 79.7)	57.8 (49.8 to 70.5)	72.5 (59.1 to 81.2)	75.1 (63.0 to 83.6)
			<50	27624 (20.5)	2801 (12.8)	150 (28.5)	337 (21.6)	400 (7.8)	127 (25.5)	1618 (12.7)	169 (10.9)
			50-69	40578 (30.1)	7387 (33.6)	172 (32.7)	761 (48.8)	1814 (35.5)	243 (48.8)	3985 (31.4)	412 (26.5)
			70-79	26902 (20.0)	6113 (27.8)	122 (23.2)	297 (19.1)	1654 (32.3)	64 (12.9)	3559 (28.0)	417 (26.8)
			80+	39482 (29.3)	5651 (25.7)	82 (15.6)	164 (10.5)	1248 (24.4)	64 (12.9)	3537 (27.8)	556 (35.8)
			(Missing)	12 (0.0)	2 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.0)	0 (0.0)
Sex at Birth	156514 (100.0)	38	Male	74429 (55.3)	11564 (52.7)	268 (51.0)	964 (61.8)	2972 (58.1)	283 (56.8)	6228 (49.0)	849 (54.6)
			Female	60001 (44.6)	10353 (47.2)	258 (49.0)	593 (38.0)	2133 (41.7)	214 (43.0)	6452 (50.8)	703 (45.2)
			Not specified	136 (0.1)	31 (0.1)	0 (0.0)	1 (0.1)	10 (0.2)	1 (0.2)	18 (0.1)	1 (0.1)
			(Missing)	32 (0.0)	6 (0.0)	0 (0.0)	1 (0.1)	1 (0.0)	0 (0.0)	3 (0.0)	1 (0.1)
Ethnicity	136128 (87.0)	20424	White	95260 (70.8)	16578 (75.5)	308 (58.6)	1018 (65.3)	4078 (79.7)	230 (46.2)	9742 (76.7)	1202 (77.3)
			South Asian	7978 (5.9)	1023 (4.7)	26 (4.9)	169 (10.8)	139 (2.7)	23 (4.6)	603 (4.7)	63 (4.1)
			Black	3998 (3.0)	603 (2.7)	95 (18.1)	73 (4.7)	95 (1.9)	118 (23.7)	194 (1.5)	28 (1.8)
			East Asian	730 (0.5)	83 (0.4)	3 (0.6)	13 (0.8)	16 (0.3)	2 (0.4)	40 (0.3)	9 (0.6)
			Other	8679 (6.4)	1196 (5.4)	39 (7.4)	125 (8.0)	261 (5.1)	54 (10.8)	630 (5.0)	87 (5.6)
			(Missing)	17953 (13.3)	2471 (11.3)	55 (10.5)	161 (10.3)	527 (10.3)	71 (14.3)	1492 (11.7)	165 (10.6)
Number of comorbidities	156552 (100.0)	0	0	24608 (18.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
			1	27784 (20.6)	1153 (5.3)	37 (7.0)	66 (4.2)	194 (3.8)	1 (0.2)	709 (5.6)	146 (9.4)
			2+	82206 (61.1)	20801 (94.7)	489 (93.0)	1493 (95.8)	4922 (96.2)	497 (99.8)	11992 (94.4)	1408 (90.6)
Chronic Cardiac Disease	141945 (90.7)	14607	No	85390 (63.4)	14351 (65.4)	372 (70.7)	1054 (67.6)	3580 (70.0)	365 (73.3)	8018 (63.1)	962 (61.9)

label	Total N	Missing N	levels	Immunocompetent	Immunocompromised – Total	Immunocompromised - Pre-Existing Immunological Disorder	Immunocompromised - Previous Organ Transplant	Immunocompromised - Cancer	Immunocompromised - HIV	Immunocompromised - Pre-Admission Immunosuppressants	Immunocompromised - Pre-Admission Steroids
			Yes	35597 (26.4)	6607 (30.1)	130 (24.7)	439 (28.2)	1318 (25.8)	107 (21.5)	4124 (32.5)	489 (31.5)
			(Missing)	13611 (10.1)	996 (4.5)	24 (4.6)	66 (4.2)	218 (4.3)	26 (5.2)	559 (4.4)	103 (6.6)
Hypertension	142801 (91.2)	13751	No	64695 (48.1)	11231 (51.2)	295 (56.1)	618 (39.6)	2870 (56.1)	265 (53.2)	6389 (50.3)	794 (51.1)
			Yes	57117 (42.4)	9758 (44.4)	206 (39.2)	893 (57.3)	2049 (40.1)	213 (42.8)	5731 (45.1)	666 (42.9)
			(Missing)	12786 (9.5)	965 (4.4)	25 (4.8)	48 (3.1)	197 (3.9)	20 (4.0)	581 (4.6)	94 (6.0)
Chronic Pulmonary Disease	141948 (90.7)	14604	No	102408 (76.1)	14855 (67.7)	387 (73.6)	1267 (81.3)	3969 (77.6)	418 (83.9)	7826 (61.6)	988 (63.6)
			Yes	18495 (13.7)	6190 (28.2)	122 (23.2)	229 (14.7)	946 (18.5)	59 (11.8)	4362 (34.3)	472 (30.4)
			(Missing)	13695 (10.2)	909 (4.1)	17 (3.2)	63 (4.0)	201 (3.9)	21 (4.2)	513 (4.0)	94 (6.0)
Chronic Renal Disease	141492 (90.4)	15060	No	101697 (75.6)	16628 (75.7)	418 (79.5)	639 (41.0)	4095 (80.0)	393 (78.9)	9884 (77.8)	1199 (77.2)
			Yes	18901 (14.0)	4266 (19.4)	88 (16.7)	865 (55.5)	790 (15.4)	79 (15.9)	2190 (17.2)	254 (16.3)
			(Missing)	14000 (10.4)	1060 (4.8)	20 (3.8)	55 (3.5)	231 (4.5)	26 (5.2)	627 (4.9)	101 (6.5)
Asthma	141767 (90.6)	14785	No	103088 (76.6)	16476 (75.0)	424 (80.6)	1342 (86.1)	4388 (85.8)	403 (80.9)	8780 (69.1)	1139 (73.3)
			Yes	17720 (13.2)	4483 (20.4)	81 (15.4)	158 (10.1)	511 (10.0)	73 (14.7)	3348 (26.4)	312 (20.1)
			(Missing)	13790 (10.2)	995 (4.5)	21 (4.0)	59 (3.8)	217 (4.2)	22 (4.4)	573 (4.5)	103 (6.6)
Liver Disease	140634 (89.8)	15918	No	116080 (86.2)	19849 (90.4)	471 (89.5)	1363 (87.4)	4625 (90.4)	434 (87.1)	11566 (91.1)	1390 (89.4)
			Yes	3800 (2.8)	905 (4.1)	29 (5.5)	121 (7.8)	229 (4.5)	37 (7.4)	436 (3.4)	53 (3.4)
			(Missing)	14718 (10.9)	1200 (5.5)	26 (4.9)	75 (4.8)	262 (5.1)	27 (5.4)	699 (5.5)	111 (7.1)
Chronic Neurological Disorder	141119 (90.1)	15433	No	106340 (79.0)	18677 (85.1)	423 (80.4)	1365 (87.6)	4479 (87.5)	418 (83.9)	10750 (84.6)	1242 (79.9)
			Yes	13957 (10.4)	2145 (9.8)	79 (15.0)	125 (8.0)	385 (7.5)	56 (11.2)	1306 (10.3)	194 (12.5)
			(Missing)	14301 (10.6)	1132 (5.2)	24 (4.6)	69 (4.4)	252 (4.9)	24 (4.8)	645 (5.1)	118 (7.6)
Malignant Neoplasm	140939 (90.0)	15613	No	111603 (82.9)	15739 (71.7)	451 (85.7)	1276 (81.8)	1509 (29.5)	439 (88.2)	10792 (85.0)	1272 (81.9)
			Yes	8484 (6.3)	5113 (23.3)	45 (8.6)	209 (13.4)	3440 (67.2)	33 (6.6)	1236 (9.7)	150 (9.7)
			(Missing)	14511 (10.8)	1102 (5.0)	30 (5.7)	74 (4.7)	167 (3.3)	26 (5.2)	673 (5.3)	132 (8.5)
Chronic Haemotologic Disease	140895 (90.0)	15657	No	116431 (86.5)	18758 (85.4)	351 (66.7)	1389 (89.1)	3742 (73.1)	442 (88.8)	11458 (90.2)	1376 (88.5)

label	Total N	Missing N	levels	Immunocompetent	Immunocompromised – Total	Immunocompromised - Pre-Existing Immunological Disorder	Immunocompromised - Previous Organ Transplant	Immunocompromised - Cancer	Immunocompromised - HIV	Immunocompromised - Pre-Admission Immunosuppressants	Immunocompromised - Pre-Admission Steroids
			Yes	3665 (2.7)	2041 (9.3)	150 (28.5)	102 (6.5)	1132 (22.1)	32 (6.4)	574 (4.5)	51 (3.3)
			(Missing)	14502 (10.8)	1155 (5.3)	25 (4.8)	68 (4.4)	242 (4.7)	24 (4.8)	669 (5.3)	127 (8.2)
Obesity	125264 (80.0)	31288	No	89557 (66.5)	15300 (69.7)	367 (69.8)	1120 (71.8)	3841 (75.1)	337 (67.7)	8543 (67.3)	1092 (70.3)
			Yes	17462 (13.0)	2945 (13.4)	69 (13.1)	185 (11.9)	466 (9.1)	80 (16.1)	2006 (15.8)	139 (8.9)
			(Missing)	27579 (20.5)	3709 (16.9)	90 (17.1)	254 (16.3)	809 (15.8)	81 (16.3)	2152 (16.9)	323 (20.8)
Diabetes	143343 (91.6)	13209	No	85844 (63.8)	15135 (68.9)	358 (68.1)	950 (60.9)	3766 (73.6)	324 (65.1)	8706 (68.5)	1031 (66.3)
			Yes	36322 (27.0)	6042 (27.5)	153 (29.1)	563 (36.1)	1188 (23.2)	162 (32.5)	3537 (27.8)	439 (28.2)
			(Missing)	12432 (9.2)	777 (3.5)	15 (2.9)	46 (3.0)	162 (3.2)	12 (2.4)	458 (3.6)	84 (5.4)
Rheumatologic Disorder	140476 (89.7)	16076	No	106762 (79.3)	16273 (74.1)	411 (78.1)	1339 (85.9)	4310 (84.2)	438 (88.0)	8586 (67.6)	1189 (76.5)
			Yes	12901 (9.6)	4540 (20.7)	82 (15.6)	138 (8.9)	559 (10.9)	33 (6.6)	3491 (27.5)	237 (15.3)
			(Missing)	14935 (11.1)	1141 (5.2)	33 (6.3)	82 (5.3)	247 (4.8)	27 (5.4)	624 (4.9)	128 (8.2)
Dementia	140670 (89.9)	15882	No	104563 (77.7)	19205 (87.5)	458 (87.1)	1432 (91.9)	4583 (89.6)	439 (88.2)	11047 (87.0)	1246 (80.2)
			Yes	15328 (11.4)	1574 (7.2)	41 (7.8)	53 (3.4)	286 (5.6)	29 (5.8)	974 (7.7)	191 (12.3)
			(Missing)	14707 (10.9)	1175 (5.4)	27 (5.1)	74 (4.7)	247 (4.8)	30 (6.0)	680 (5.4)	117 (7.5)
Malnutrition	131191 (83.8)	25361	No	109531 (81.4)	18749 (85.4)	443 (84.2)	1353 (86.8)	4346 (84.9)	425 (85.3)	10888 (85.7)	1294 (83.3)
			Yes	2417 (1.8)	494 (2.3)	11 (2.1)	34 (2.2)	160 (3.1)	15 (3.0)	249 (2.0)	25 (1.6)
			(Missing)	22650 (16.8)	2711 (12.3)	72 (13.7)	172 (11.0)	610 (11.9)	58 (11.6)	1564 (12.3)	235 (15.1)
Smoking	81789 (52.2)	74763	No	35378 (26.3)	5587 (25.4)	165 (31.4)	447 (28.7)	1271 (24.8)	164 (32.9)	3214 (25.3)	326 (21.0)
			Yes	33798 (25.1)	7026 (32.0)	118 (22.4)	347 (22.3)	1621 (31.7)	109 (21.9)	4363 (34.4)	468 (30.1)
			(Missing)	65422 (48.6)	9341 (42.5)	243 (46.2)	765 (49.1)	2224 (43.5)	225 (45.2)	5124 (40.3)	760 (48.9)
Vaccination Dose on Admission	153293 (97.9)	3259	Unvaccinated	114364 (85.0)	17737 (80.8)	452 (85.9)	1078 (69.1)	4077 (79.7)	419 (84.1)	10267 (80.8)	1444 (92.9)
			First Dose	5112 (3.8)	789 (3.6)	6 (1.1)	60 (3.8)	166 (3.2)	17 (3.4)	516 (4.1)	24 (1.5)
			Second Dose	11601 (8.6)	2804 (12.8)	49 (9.3)	344 (22.1)	679 (13.3)	41 (8.2)	1631 (12.8)	60 (3.9)
			Third Dose	592 (0.4)	290 (1.3)	6 (1.1)	51 (3.3)	92 (1.8)	1 (0.2)	139 (1.1)	1 (0.1)
			Fourth Dose	2 (0.0)	2 (0.0)	0 (0.0)	0 (0.0)	2 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

label	Total N	Missing N	levels	Immunocompetent	Immunocompromised – Total	Immunocompromised - Pre-Existing Immunological Disorder	Immunocompromised - Previous Organ Transplant	Immunocompromised - Cancer	Immunocompromised - HIV	Immunocompromised - Pre-Admission Immunosuppressants	Immunocompromised - Pre-Admission Steroids
			(Missing)	2927 (2.2)	332 (1.5)	13 (2.5)	26 (1.7)	100 (2.0)	20 (4.0)	148 (1.2)	25 (1.6)

# Table 2. Outcomes stratified by immune status and pandemic wave.

label	levels	Immunocompetent - Wave 1	Immunocompromised - Wave 1	Immunocompetent - Wave 2	Immunocompromised - Wave 2	Immunocompetent - Wave 3	Immunocompromised - Wave 3	Immunocompetent – Wave 4	Immunocompromised – Wave 4
Oxygen	No	10974 (31.2)	1910 (28.0)	16398 (25.7)	2227 (22.8)	7745 (29.0)	1029 (24.0)	3659 (51.6)	361 (40.1)
	Yes	24227 (68.8)	4918 (72.0)	47468 (74.3)	7549 (77.2)	18999 (71.0)	3258 (76.0)	3434 (48.4)	540 (59.9)
Critical Care Admission	No	30785 (86.9)	5952 (86.9)	52873 (82.5)	8101 (82.7)	22469 (83.9)	3514 (82.0)	6611 (92.4)	823 (90.8)
	Yes	4637 (13.1)	896 (13.1)	11223 (17.5)	1693 (17.3)	4306 (16.1)	773 (18.0)	544 (7.6)	83 (9.2)
Non-Invasive Ventilation	No	29970 (85.4)	5660 (83.2)	50363 (79.4)	7449 (76.8)	20925 (78.9)	3181 (74.7)	6362 (90.1)	762 (84.9)
	Yes	5106 (14.6)	1145 (16.8)	13035 (20.6)	2252 (23.2)	5608 (21.1)	1078 (25.3)	696 (9.9)	136 (15.1)
Invasive Ventilation	No	32524 (92.4)	6384 (93.6)	59058 (93.0)	8973 (92.2)	25074 (94.7)	3948 (92.8)	6875 (97.6)	866 (96.7)
	Yes	2664 (7.6)	435 (6.4)	4416 (7.0)	754 (7.8)	1415 (5.3)	308 (7.2)	170 (2.4)	30 (3.3)
Death	No	24766 (70.2)	4379 (64.3)	48439 (77.4)	6551 (68.6)	23276 (87.9)	3317 (78.3)	5726 (88.7)	662 (81.2)
	Yes	10495 (29.8)	2430 (35.7)	14177 (22.6)	2998 (31.4)	3210 (12.1)	918 (21.7)	726 (11.3)	153 (18.8)

Figure 1. Illness severity and characteristics of the patients. (A) Illness severity over the course of the pandemic, measured using the 4C Mortality Score by immune status and pandemic wave. Pink bars: immunocompetent, green bars: immunocompromised. (B) Physiological components of the 4C Mortality Score stratified by immune status and pandemic wave. (C) Overlap between immunocompromising conditions А



# Immunocompromise Overlap





Figure 2. Outcomes of hospitalised immunocompromised patients, compared with immunocompetent patients. Odds ratios (ORs) from multivariable logistic regression and 95% confidence intervals (CI) for (A) outcomes of death, oxygen use, critical care admission, non-invasive and invasive ventilation, and (B) for death in the first 4 pandemic waves in the UK. ORs are adjusted for age, sex, ethnicity, deprivation, and comorbidities.

### А



Odds ratio (95% CI, log scale)

Figure 3: Absolute risk difference (ARD) for death between immunocompromised and immunocompetent. The difference in risk of death in the first wave, and the fourth wave, for immunocompetent and immunocompromised patients was modelled using Bayesian logistic regression, and the probability that the risk of death across the two waves reduced more in the immunocompetent that the immunocompromised was calculated. The analysis was stratified by age and sex.



Absolute risk difference for death between immunocompromised and immunocompetent Wave 4 vs wave 1: greater difference in risk in wave 4 vs wave 1 for older immunocompromised

### Supplementary data

### Table S1. Comorbidities in immunocompetent versus immunocompromised patients stratified by pandemic wave.

label	levels	Immunocom petent - Wave 1	Immunocompr omised - Wave 1	Immunocom petent - Wave 2	Immunocompr omised - Wave 2	Immunocom petent - Wave 3	Immunocompr omised - Wave 3	Immunocom petent – Wave 4	Immunocompr omised – Wave 4
Age on admission (years)	Median (IQR)	75.3 (59.7 to 84.9)	74.1 (62.0 to 82.5)	70.2 (55.6 to 81.9)	71.3 (59.0 to 80.1)	58.7 (42.2 to 75.2)	66.9 (53.9 to 76.6)	66.8 (45.5 to 81.5)	69.2 (56.2 to 78.6)
	<50	4716 (13.3)	641 (9.3)	10867 (16.8)	1209 (12.3)	9867 (36.4)	806 (18.6)	2174 (29.4)	145 (15.7)
	50-69	9402 (26.5)	2010 (29.3)	21188 (32.8)	3389 (34.4)	8129 (30.0)	1658 (38.3)	1859 (25.2)	330 (35.8)
	70-79	7472 (21.0)	1977 (28.8)	13751 (21.3)	2764 (28.1)	4381 (16.2)	1110 (25.7)	1298 (17.6)	262 (28.4)
	80+	13931 (39.2)	2230 (32.5)	18755 (29.1)	2485 (25.2)	4738 (17.5)	751 (17.4)	2058 (27.9)	185 (20.1)
Sex at Birth	Male	19501 (54.9)	3684 (53.7)	36124 (56.0)	5196 (52.8)	15137 (55.8)	2234 (51.7)	3667 (49.6)	450 (48.8)
	Female	15976 (45.0)	3163 (46.1)	28371 (43.9)	4636 (47.1)	11948 (44.1)	2083 (48.2)	3706 (50.2)	471 (51.1)
	Not specified	41 (0.1)	8 (0.1)	60 (0.1)	15 (0.2)	22 (0.1)	7 (0.2)	13 (0.2)	1 (0.1)
Ethnicity	White	25322 (82.0)	5207 (85.0)	46492 (82.5)	7399 (85.0)	18501 (79.8)	3262 (85.0)	4945 (79.7)	710 (86.8)
	South Asian	1856 (6.0)	300 (4.9)	4094 (7.3)	490 (5.6)	1610 (6.9)	201 (5.2)	418 (6.7)	32 (3.9)
	Black	1159 (3.8)	220 (3.6)	1542 (2.7)	229 (2.6)	999 (4.3)	127 (3.3)	298 (4.8)	27 (3.3)
	East Asian	243 (0.8)	30 (0.5)	307 (0.5)	38 (0.4)	158 (0.7)	14 (0.4)	22 (0.4)	1 (0.1)
	Other	2313 (7.5)	368 (6.0)	3920 (7.0)	547 (6.3)	1924 (8.3)	233 (6.1)	522 (8.4)	48 (5.9)
Number of comorbidi ties	0	4378 (12.3)	0 (0.0)	10230 (15.8)	0 (0.0)	8238 (30.4)	0 (0.0)	1762 (23.8)	0 (0.0)
	1	6868 (19.3)	285 (4.2)	13649 (21.1)	489 (5.0)	5809 (21.4)	335 (7.7)	1458 (19.7)	44 (4.8)
	2+	24279 (68.3)	6573 (95.8)	40688 (63.0)	9359 (95.0)	13070 (48.2)	3991 (92.3)	4169 (56.4)	878 (95.2)
Chronic Cardiac Disease	No	22615 (66.7)	4261 (64.8)	43530 (71.4)	6571 (69.2)	15241 (75.5)	2924 (72.8)	4004 (68.1)	595 (68.0)
	Yes	11298 (33.3)	2315 (35.2)	17470 (28.6)	2918 (30.8)	4955 (24.5)	1094 (27.2)	1874 (31.9)	280 (32.0)
Hyperten sion	No	17156 (50.4)	3495 (53.1)	32532 (52.9)	5060 (53.2)	11717 (57.5)	2176 (54.1)	3290 (55.7)	500 (57.3)
	Yes	16889 (49.6)	3083 (46.9)	28933 (47.1)	4456 (46.8)	8674 (42.5)	1846 (45.9)	2621 (44.3)	373 (42.7)
Chronic Pulmonar y Disease	No	28521 (84.6)	4602 (69.9)	52034 (85.3)	6752 (70.8)	17117 (84.5)	2920 (72.3)	4736 (80.2)	581 (65.6)
	Yes	5189 (15.4)	1983 (30.1)	8999 (14.7)	2784 (29.2)	3138 (15.5)	1118 (27.7)	1169 (19.8)	305 (34.4)
Chronic Renal Disease	No	27710 (82.3)	5149 (78.8)	51719 (85.0)	7677 (81.1)	17395 (86.2)	3132 (78.0)	4873 (82.7)	670 (76.4)
	Yes	5961 (17.7)	1386 (21.2)	9136 (15.0)	1791 (18.9)	2784 (13.8)	882 (22.0)	1020 (17.3)	207 (23.6)
Asthma	No	29546 (87.7)	5269 (80.7)	52021 (85.4)	7369 (77.5)	16569 (81.7)	3138 (77.6)	4952 (84.0)	700 (79.5)
	Yes	4150 (12.3)	1257 (19.3)	8922 (14.6)	2140 (22.5)	3705 (18.3)	905 (22.4)	943 (16.0)	181 (20.5)
Liver Disease	No	32281 (96.7)	6204 (95.8)	58724 (96.9)	8987 (95.5)	19463 (96.8)	3833 (95.8)	5612 (96.6)	825 (95.3)
	Yes	1112 (3.3)	274 (4.2)	1856 (3.1)	422 (4.5)	635 (3.2)	168 (4.2)	197 (3.4)	41 (4.7)

label	levels	Immunocom petent - Wave 1	Immunocompr omised - Wave 1	Immunocom petent - Wave 2	Immunocompr omised - Wave 2	Immunocom petent - Wave 3	Immunocompr omised - Wave 3	Immunocom petent – Wave 4	Immunocompr omised – Wave 4
Chronic Neurologi cal Disorder	No	28925 (86.2)	5729 (88.1)	54021 (89.0)	8478 (89.9)	18345 (90.9)	3691 (92.0)	5049 (86.4)	779 (89.1)
	Yes	4640 (13.8)	776 (11.9)	6678 (11.0)	953 (10.1)	1844 (9.1)	321 (8.0)	795 (13.6)	95 (10.9)
Malignant Neoplasm	No	31019 (92.8)	4857 (74.6)	56420 (93.0)	7206 (76.2)	18895 (93.8)	3048 (76.2)	5269 (90.5)	628 (71.4)
	Yes	2423 (7.2)	1656 (25.4)	4256 (7.0)	2252 (23.8)	1250 (6.2)	953 (23.8)	555 (9.5)	252 (28.6)
Chronic Haemotol ogic Disease	No	32397 (96.9)	5796 (89.4)	58907 (97.1)	8596 (91.2)	19535 (96.9)	3600 (89.6)	5592 (95.9)	766 (87.8)
	Yes	1039 (3.1)	690 (10.6)	1761 (2.9)	829 (8.8)	623 (3.1)	416 (10.4)	242 (4.1)	106 (12.2)
Obesity	No	26042 (87.3)	5016 (87.5)	44460 (82.9)	6693 (81.8)	14327 (79.0)	2886 (82.0)	4728 (87.3)	705 (87.0)
	Yes	3793 (12.7)	717 (12.5)	9167 (17.1)	1489 (18.2)	3815 (21.0)	634 (18.0)	687 (12.7)	105 (13.0)
Diabetes	No	23631 (69.0)	4669 (70.3)	43534 (70.7)	6874 (71.7)	14424 (70.6)	2915 (71.8)	4255 (71.9)	677 (76.2)
	Yes	10602 (31.0)	1970 (29.7)	18061 (29.3)	2716 (28.3)	5995 (29.4)	1145 (28.2)	1664 (28.1)	211 (23.8)
Rheumat ologic Disorder	No	29815 (89.5)	5105 (78.8)	53567 (88.7)	7351 (77.9)	18101 (90.1)	3116 (77.5)	5279 (90.3)	701 (79.8)
	Yes	3487 (10.5)	1374 (21.2)	6858 (11.3)	2084 (22.1)	1992 (9.9)	905 (22.5)	564 (9.7)	177 (20.2)
Dementia	No	26981 (80.4)	5772 (88.7)	53735 (89.0)	8762 (93.3)	18717 (93.1)	3834 (95.9)	5130 (87.9)	837 (94.9)
	Yes	6588 (19.6)	735 (11.3)	6651 (11.0)	629 (6.7)	1380 (6.9)	165 (4.1)	709 (12.1)	45 (5.1)
Malnutriti on	No	30161 (97.0)	5841 (97.0)	55152 (97.9)	8391 (97.1)	18759 (98.8)	3696 (98.7)	5459 (98.3)	821 (98.0)
	Yes	929 (3.0)	181 (3.0)	1164 (2.1)	249 (2.9)	227 (1.2)	47 (1.3)	97 (1.7)	17 (2.0)
Smoking	No	9736 (52.1)	1741 (44.1)	18467 (52.5)	2578 (45.1)	5785 (47.8)	1082 (44.5)	1390 (43.2)	186 (35.6)
	Yes	8969 (47.9)	2206 (55.9)	16682 (47.5)	3132 (54.9)	6319 (52.2)	1352 (55.5)	1828 (56.8)	336 (64.4)
Vaccinati on Dose on Admissio n	Unvacci nated	34396 (100.0)	6688 (100.0)	59598 (94.9)	9143 (94.4)	13488 (49.7)	1058 (24.5)	6882 (93.1)	848 (92.0)
	First Dose	0 (0.0)	0 (0.0)	3116 (5.0)	532 (5.5)	1948 (7.2)	253 (5.8)	48 (0.6)	4 (0.4)
	Second Dose	0 (0.0)	0 (0.0)	55 (0.1)	11 (0.1)	11251 (41.5)	2762 (63.8)	295 (4.0)	31 (3.4)
	Third Dose	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	428 (1.6)	251 (5.8)	164 (2.2)	39 (4.2)
	Fourth Dose	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.0)	2 (0.0)	0 (0.0)	0 (0.0)

Table S2. Disease severity by immune status and pandemic wave. The 4C mortality score is calculated on admission to hosptial from age, sex, number of comorbidities, respiratory rate, oxygen saturation, Glasgow coma scale, urea and CRP. The score ranges from 0 (low risk) to 21 (very high risk). Score 0-3 = low risk (1.2% mortality), 4-8 = intermediate risk (9.9% mortality), 9-14 = high risk (31.4% mortality) and 15-21 = very high risk (61.5% mortality).

label	level s	Immunocom petent - Wave 1	Immunocompro mised - Wave 1	Immunocom petent - Wave 2	Immunocompro mised - Wave 2	Immunocom petent - Wave 3	Immunocompro mised - Wave 3	Immunocom petent – Wave 4	Immunocompro mised – Wave 4
ISARIC4 C Mortality Score	Med ian (IQR )	11.0 (8.0 to 13.0)	11.0 (9.0 to 13.0)	10.0 (7.0 to 13.0)	11.0 (8.0 to 13.0)	8.0 (4.0 to 11.0)	10.0 (7.0 to 12.0)	9.0 (4.0 to 12.0)	10.0 (7.0 to 12.0)
Respirat ory Rate (breaths per min)	<20	12159 (35.1)	2259 (33.6)	20832 (33.1)	3060 (31.6)	8563 (32.5)	1291 (30.3)	2453 (42.6)	283 (33.0)
	20- 30	16963 (48.9)	3382 (50.4)	33071 (52.5)	5173 (53.5)	14210 (54.0)	2406 (56.5)	2726 (47.4)	463 (54.0)
	>=3 0	5558 (16.0)	1074 (16.0)	9102 (14.4)	1439 (14.9)	3545 (13.5)	564 (13.2)	578 (10.0)	112 (13.1)
Number of comorbid ities	0	4378 (12.3)	0 (0.0)	10230 (15.8)	0 (0.0)	8238 (30.4)	0 (0.0)	1762 (23.8)	0 (0.0)
	1	6868 (19.3)	285 (4.2)	13649 (21.1)	489 (5.0)	5809 (21.4)	335 (7.7)	1458 (19.7)	44 (4.8)
	2+	24279 (68.3)	6573 (95.8)	40688 (63.0)	9359 (95.0)	13070 (48.2)	3991 (92.3)	4169 (56.4)	878 (95.2)
Oxygen Saturatio n (%)	>=9 2	27589 (79.2)	5254 (77.7)	49645 (78.6)	7421 (76.6)	21201 (80.0)	3323 (77.9)	4912 (84.9)	671 (77.7)
	<92	7244 (20.8)	1507 (22.3)	13495 (21.4)	2262 (23.4)	5288 (20.0)	942 (22.1)	875 (15.1)	193 (22.3)
Glasgow Coma Score	15	27882 (84.5)	5664 (88.2)	55467 (90.9)	8585 (91.8)	24134 (93.9)	3872 (94.0)	5403 (91.0)	771 (92.2)
	<15	5128 (15.5)	756 (11.8)	5534 (9.1)	767 (8.2)	1562 (6.1)	249 (6.0)	533 (9.0)	65 (7.8)
Blood Urea (mmol/L)	<7	13721 (48.4)	2633 (47.2)	28504 (54.9)	4109 (50.9)	14805 (66.2)	1877 (51.3)	3024 (61.3)	378 (51.5)
	7-14	9659 (34.0)	2027 (36.3)	17073 (32.9)	2927 (36.3)	5636 (25.2)	1291 (35.3)	1355 (27.5)	258 (35.1)
	>14	4998 (17.6)	919 (16.5)	6320 (12.2)	1032 (12.8)	1927 (8.6)	490 (13.4)	557 (11.3)	98 (13.4)
C- Reactive Protein (mg/L)	<50	10342 (35.9)	1932 (33.9)	18415 (35.5)	2658 (32.8)	8349 (36.8)	1261 (33.9)	2552 (52.8)	307 (42.1)
	50- 99	6632 (23.0)	1400 (24.6)	13312 (25.7)	2160 (26.7)	5556 (24.5)	1005 (27.0)	892 (18.5)	167 (22.9)
	>=1 00	11824 (41.1)	2363 (41.5)	20110 (38.8)	3277 (40.5)	8757 (38.6)	1455 (39.1)	1385 (28.7)	256 (35.1)

### Table S3. Number (%) of patients receiving steroids and tocilizumab by immune status and pandemic wave.

label	level s	Immunocom petent - Wave 1	Immunocompr omised - Wave 1	Immunocom petent - Wave 2	Immunocompr omised - Wave 2	Immunocom petent - Wave 3	Immunocompr omised - Wave 3	Immunocom petent – Wave 4	Immunocompr omised – Wave 4
Steroids	No	20192 (83.3)	2405 (48.9)	7721 (16.3)	824 (10.9)	2223 (11.7)	277 (8.5)	1246 (36.3)	101 (18.7)
	Yes	4035 (16.7)	2513 (51.1)	39747 (83.7)	6725 (89.1)	16776 (88.3)	2981 (91.5)	2188 (63.7)	439 (81.3)
Tociliz umab	N o	12340 (99.5)	2482 (99.6)	21610 (93.7)	3529 (95.5)	7812 (80.4)	1422 (85.0)	1107 (86.7)	206 (88.8)
	Y e s	59 (0.5)	11 (0.4)	1456 (6.3)	167 (4.5)	1900 (19.6)	251 (15.0)	170 (13.3)	26 (11.2)

### Table S4. Outcomes by reason for immunocompromise.

label	levels	Immunocompetent	Pre-Existing Immunological Disorder	Previous Organ Transplant	Cancer	HIV/AIDS	Pre-Admission Immunosuppressants	Pre- Admission Steroids
Oxygen	No	38776 (29.2)	151 (29.2)	471 (30.6)	1555 (30.7)	142 (29.0)	2858 (22.6)	350 (22.7)
	Yes	94128 (70.8)	367 (70.8)	1070 (69.4)	3516 (69.3)	348 (71.0)	9769 (77.4)	1195 (77.3)
Critical Care Admission	No	112738 (84.5)	421 (81.1)	1209 (78.2)	4437 (87.3)	367 (74.1)	10637 (84.1)	1319 (85.2)
	Yes	20710 (15.5)	98 (18.9)	337 (21.8)	648 (12.7)	128 (25.9)	2005 (15.9)	229 (14.8)
Non-Invasive Ventilation	No	107620 (81.5)	416 (80.5)	1170 (76.2)	4127 (81.8)	369 (75.8)	9758 (77.7)	1212 (79.5)
	Yes	24445 (18.5)	101 (19.5)	365 (23.8)	918 (18.2)	118 (24.2)	2796 (22.3)	313 (20.5)
Invasive Ventilation	No	123531 (93.4)	471 (90.9)	1365 (88.9)	4820 (95.3)	428 (87.9)	11672 (92.9)	1415 (92.4)
	Yes	8665 (6.6)	47 (9.1)	171 (11.1)	236 (4.7)	59 (12.1)	898 (7.1)	116 (7.6)
Death	No	102207 (78.1)	391 (75.9)	1100 (72.8)	3168 (63.5)	396 (81.6)	8849 (71.4)	1005 (66.0)
	Yes	28608 (21.9)	124 (24.1)	411 (27.2)	1818 (36.5)	89 (18.4)	3540 (28.6)	517 (34.0)

### Figure S1: Consort diagram





Figure S2. Admissions stratified by the number of vaccine doses received Rolling Monthly Average Hospital Admission by Vaccine Uptake over Time





Figure S4. Tocilizumab usage by immune status in the first 4 pandemic waves in the UK



Figure S5. Outcome of hospitalised immunocompromised patients, compared with immunocompetent patients. Odds ratios (OR) for in-hospital death from univariable logistic regression in each of the first four pandemic waves in the UK.



# Figure S6. Number of admissions of immunocompetent and immunocompromised patients over time

